Announcement of Manufacture and Supply of Pharmaceutical Intermediates for "Avigan® Tablet"

  • Press release
  • UP
  • jnc

JNC CORPORATION (Chiyoda-ku, Tokyo, CEO & President: Keizo Yamada) announces that the plants in Minamata Factory (Minamata, Kumamoto) will manufacture and start supply of pharmaceutical intermediate for "Avigan® Tablet" (generic name: favipiravir, hereinafter "Avigan"), an influenza antiviral drug developed by FUJIFILM Toyama Chemical Co., Ltd.

◊ - - ◊ - - ◊ - - ◊

"Avigan" is expected to be effective in treating the novel coronavirus infection (COVID-19) that has become a global pandemic.

Our company immediately determined measures in response to the cooperation request from FUJIFILM Corporation for manufacturing pharmaceutical intermediate for "Avigan," and made the decision to start production from the end of April.

We manufacture not only intermediates for pharmaceuticals but also (wide variety of) chemicals, and continue to advance "Manufacturing" for contributing to society as a chemicals manufacturer.


[Contact Information]

03-3243-6370 General Affairs Dept., JNC CORPORATION